A 64-year-old woman with a history of stage IV pancreatic cancer is hospitalized for a painful, swollen left lower extremity. A Doppler ultrasound confirms a proximal deep vein thrombosis (DVT). The medical team decides to initiate anticoagulation with subcutaneous enoxaparin.
Which of the following best describes the primary mechanism of action of this medication?
The correct answer is:
A) Binding to antithrombin III to primarily inactivate Factor Xa
Low-molecular-weight heparin (LMWH), such as enoxaparin or dalteparin, is derived from unfractionated heparin (UFH) through chemical or enzymatic depolymerization. Like UFH, it acts by binding to antithrombin III (ATIII) via a specific pentasaccharide sequence. However, because LMWH chains are significantly shorter than those of UFH, they lack the physical length required to bridge antithrombin to thrombin (Factor IIa). As a result, LMWH is much more efficient at inactivating Factor Xa than thrombin, typically exhibiting a Factor Xa to Factor IIa activity ratio of 2:1 to 4:1.
Answer choice B: Direct inhibition of the active site of Factor Xa, is incorrect. This describes the mechanism of direct oral anticoagulants (DOACs) like rivaroxaban and apixaban. These drugs bind directly to Factor Xa and do not require antithrombin III as a cofactor.
Answer choice C: Formation of a ternary complex with antithrombin and thrombin, is incorrect. This is the primary mechanism of unfractionated heparin (UFH). UFH is long enough to wrap around both ATIII and thrombin simultaneously, leading to a 1:1 ratio of Xa and IIa inhibition.
Answer choice D: Inhibition of vitamin K epoxide reductase, is incorrect. This is the mechanism of warfarin, which prevents the recycling of vitamin K and thus the activation of Factors II, VII, IX, and X.
Answer choice E: Irreversible blockade of the P2Y12 receptor, is incorrect. This describes the mechanism of thienopyridine antiplatelet agents like clopidogrel. LMWH affects the coagulation cascade (secondary hemostasis), not the platelet plug (primary hemostasis).
Key Learning Point
Low-molecular-weight heparin (LMWH) provides a more predictable pharmacological response than UFH because it binds less to plasma proteins and macrophages. It has a longer half-life and is primarily cleared by the kidneys, making it contraindicated or requiring dose adjustment in patients with advanced kidney disease (CrCl <30 mL/min). Unlike UFH, routine monitoring with PTT is not required, though Anti-Xa levels can be checked in obese or pregnant patients.
